You just read:

Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab

News provided by

Alkermes plc

10 Sep, 2018, 12:00 BST